Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare prevalence of pT3/T4 categories (in reference to UICC 2002 criteria, Appendix F) between subjects receiving panitumumab plus epirubicin, cisplatin and capecitabine (ECX) versus subjects treated with ECX chemotherapy alone.
Critère d'inclusion
- Subjects with Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction